Search tips
Search criteria 


Logo of canmedajCMAJ Information for AuthorsCMAJ Home Page
Can Med Assoc J. 1983 January 1; 128(1): 24–26.
PMCID: PMC1874707

The status of metformin in Canada.


During the 1970s two biguanide drugs, phenformin and metformin, were used to control hyperglycemia. Phenformin was phased out of the Canadian market because it carried an unacceptable risk of causing lactic acidosis, but metformin remains available. All documented cases of lactic acidosis associated with metformin administration, which are rare, have occurred abroad in patients who were taking the drug in spite of having contraindications to its use. The two drugs are metabolized differently, phenformin being deactivated and concentrated in the liver, and metformin being excreted rapidly, unchanged, by the kidneys. In properly selected diabetic patients therapeutic doses of metformin do not raise the blood levels of intermediary metabolites enough to induce ketoacidosis or lactic acidosis. The safety of the drug is supported by the clinical experience over about 56,000 patient-years in Canada.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (684K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Joncas F. Quatre années d'étude clinique de la metformine chez 47 patients diabétiques. Union Med Can. 1972 Jan;101(1):65–70. [PubMed]
  • Sargent EN. Renal function following double dose infusion intravenous cholangiography. West J Med. 1974 Feb;120(2):145–145. [PMC free article] [PubMed]
  • Hunt JA, Catellier C, Dupre J, Gardiner RJ, McKendry JB, Toews CJ, Yip CC. The use of phenformin and metformin. Can Med Assoc J. 1977 Sep 3;117(5):429–430. [PMC free article] [PubMed]
  • Biron P. Metformin monitoring. Can Med Assoc J. 1978 Jan 7;118(1):15–18. [PMC free article] [PubMed]
  • Hermann LS. Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab. 1979 Sep;5(3):233–245. [PubMed]
  • Shenfield GM, Bhalla IP, Steel JM, Duncan LJ. Metformin in the treatment of obese diabetics. Practitioner. 1977 Nov;219(1313):745–749. [PubMed]
  • Holle A, Mangels W, Dreyer M, Kühnau J, Rüdiger HW. Biguanide treatment increases the number of insulin-receptor sites on human erythrocytes. N Engl J Med. 1981 Sep 3;305(10):563–566. [PubMed]
  • Shenfield GM, Campbell CJ, Duncan LJ. Hyperlipidaemia and treatment of diabetes. Practitioner. 1979 Jan;222(1327):111–113. [PubMed]
  • Pentikäinen PJ, Neuvonen PJ, Penttilä A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol. 1979 Sep;16(3):195–202. [PubMed]
  • Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981 Aug;12(2):235–246. [PubMed]
  • Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G, Bondioli A, Conti F. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther. 1978 Dec;24(6):683–693. [PubMed]
  • Nattrass M, Hinks L, Smythe P, Todd PG, Alberti KG. Metabolic effects of combined sulphonylurea and metformin therapy in maturity-onset diabetice. Horm Metab Res. 1979 May;11(5):332–337. [PubMed]
  • Dubas TC, Johnson WJ. Metformin-induced lactic acidosis: potentiation by ethanol. Res Commun Chem Pathol Pharmacol. 1981 Jul;33(1):21–31. [PubMed]
  • Waters AK, Morgan DB, Wales JK. Blood lactate and pyruvate levels in diabetic patients treated with biguanides with and without sulphonylureas. Diabetologia. 1978 Feb;14(2):95–98. [PubMed]
  • Bolzano K. Biguanide: Gründe für die Rücknahme von Präparaten und verbleibende Indikationen. Acta Med Austriaca. 1978;5(3):85–88. [PubMed]
  • Phillips PJ, Scicchitano R, Clarkson AR, Gilmore HR. Metformin associated lactic acidosis. Aust N Z J Med. 1978 Jun;8(3):281–284. [PubMed]
  • Korhonen T, Idänpän-Heikkilä J, Aro A. Biguanide-induced lactic acidosis in Finland. Eur J Clin Pharmacol. 1979 Jul;15(6):407–410. [PubMed]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association